This month PharmaTimes presents Alantra’s annual ranking of the fastest growing pharma companies in the UK. In this year’s ranking, no business with two-year average growth of less than 12% made the grade – and in top place, Exscientia delivered a stunning 98%.
More ›
Immunocore’s upsized initial public offering in NASDAQ of 9,935,896 American Depositary Shares (“ADSs”) representing 9,935,896 ordinary shares at an initial public offering price of $26.00 per ADS, for total gross proceeds of approximately $258 million. The first day’s closing price jumps 66.15% to $43.2 per ADS, which represents a market cap of $1.796B. Immunocore is a late-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies called ImmTAX - Immune mobilizing monoclonal TCRs Against X disease - designed to treat a broad range of diseases, including cancer, infectious and autoimmune. Immunocore's most advanced oncology therapeutic candidate, tebentafusp, demonstrates superior overall survival compared to investigator’s choice in a Phase 3 clinical trial of patients with previously untreated metastatic uveal melanoma.
More ›
Anastomoses technology developer GI Windows Medical announced that it raised $16.4 million in a Series A-1 financing round. West Bridgewater, Mass.-based GI Windows said in a news release that Johnson &. Johnson Innovation, Sonder Capital, GT Healthcare, JC Investco and an additional strategic investor contributed to the funding round. In addition to the institutional financing, GI Windows said it received investments from existing shareholders, along with new investors, the Kennedy Trust and Coleman Trust. The company is earmarking the proceeds from the financing for further product development and clinical studies for its technology.
More ›
Financing Co-Led by ARCH Venture Partners and Cowen Healthcare Investments Deep Leadership Expertise in Thyroid Hormone Biology, Medicinal Chemistry and Neurology
More ›
26th May 2020, Oxford, Copenhagen, and Hamburg – Exscientia, the world leading artificial intelligence (AI) drug discovery company, today announced it has raised $60 million in a Series C financing round. The financing round has been led by new investor Novo Holdings with existing investors – Evotec, Bristol Myers Squibb, and GT Healthcare Capital (through its LPs) – participating in the round. Robert Ghenchev, Senior Partner and Head of Novo Growth, the growth equity arm of Novo Holdings, joins Exscientia’s board of directors as part of the financing round.
More ›
Public Sector Pension Investment Board (PSP Investments), a large, Canada-based pension investment manager focused on long-term investments, led the funding, according to a news release. Existing investors TPG’s The Rise Fund, KCK Group, Sofinnova Partners, Venrock, T. Rowe Price, Pfizer Ventures and Johnson & Johnson Innovation, JJDC Inc. all participated in the round. BofA Securities and Morgan Stanley acted as placement agents.
More ›